View Future GrowthGenolution 過去の業績過去 基準チェック /06Genolutionの収益は年間平均-77.6%の割合で減少していますが、 Life Sciences業界の収益は年間 減少しています。収益は年間4.1% 62.9%割合で 減少しています。主要情報-77.59%収益成長率-77.72%EPS成長率Life Sciences 業界の成長53.72%収益成長率-62.85%株主資本利益率-18.55%ネット・マージン-123.80%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.すべての更新を表示Recent updatesお知らせ • Mar 17Genolution Inc., Annual General Meeting, Mar 27, 2026Genolution Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea分析記事 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • Mar 08Genolution Inc., Annual General Meeting, Mar 28, 2025Genolution Inc., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South KoreaNew Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩44.5b market cap, or US$31.7m).New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩86.0b market cap, or US$64.6m).New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩73.9b market cap, or US$53.5m).お知らせ • Jul 12Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Hana Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on January 9, 2024. As of July 9, 2023, the company had 656,993 treasury shares within scope available for dividend and no shares in treasury through other repurchase.Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩4,785, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 35% over the past three years.Upcoming Dividend • Dec 21Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.お知らせ • Oct 06Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Shinyoung Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on April 5, 2023. As of October 5, 2022, the company had 516,512 treasury shares within scope available for dividend and no shares in treasury through other repurchase.Upcoming Dividend • Sep 22Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 31 October 2022. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩14,600, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 503% over the past three years.Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩15,550, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 398% over the past three years.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩13,400, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 285% over the past three years.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩20,900, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 30x in the Life Sciences industry in South Korea. Total returns to shareholders of 415% over the past three years.お知らせ • Jun 09Genolution Inc. announced that it has received KRW 5 billion in fundingOn June 8, 2021, Genolution Inc. closed the transaction.お知らせ • Jun 05Genolution Inc. announced that it expects to receive KRW 5 billion in fundingGenolution Inc. (KOSDAQ:A225220) announced a private placement of non-guaranteed private convertible bonds for gross proceeds of KRW 5,000,000,000 on June 4, 2021. The transaction will involve participation from new investors including trustee funds 1, 2 managed by KB Securities Co., Ltd for KRW 1,000,000,000 and trustee fund 3 managed by NH Investment & Securities Co., Ltd for KRW 4,000,000,000. The bonds were issued at an interest rate of 1% and maturity rate of 1%.The bonds will be fully convertible into 315,417 common shares of the company at a fixed conversion price of KRW 15,852 per share between June 8, 2022 and May 8, 2026. The bonds will mature on June 08, 2026. The subscription date for the bonds is May 20, 2021 and payment date for the bonds is June 08, 2021. The transaction has been approved by the board of directors of the company.Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩17,850, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 72x in the Life Sciences industry in South Korea. Total returns to shareholders of 331% over the past three years.分析記事 • Mar 17Could The Genolution Inc. (KOSDAQ:225220) Ownership Structure Tell Us Something Useful?If you want to know who really controls Genolution Inc. ( KOSDAQ:225220 ), then you'll have to look at the makeup of...Is New 90 Day High Low • Mar 10New 90-day low: ₩24,550The company is down 10.0% from its price of ₩27,300 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 15% over the same period.Is New 90 Day High Low • Jan 29New 90-day low: ₩24,800The company is down 36% from its price of ₩38,600 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period.Is New 90 Day High Low • Nov 24New 90-day low: ₩25,800The company is down 26% from its price of ₩35,050 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.Is New 90 Day High Low • Nov 03New 90-day high: ₩43,600The company is up 4.0% from its price of ₩41,750 on 05 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 4.0% over the same period.お知らせ • Jul 18Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion.Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 824,000 Price\Range: KRW 14000 Discount Per Security: KRW 840 Transaction Features: ESOP Related Offering収支内訳Genolution の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A225220 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Dec 259,404-11,6439,48147230 Sep 259,146-8,0599,96860930 Jun 258,767-10,2579,60393331 Mar 257,942-8,9398,6661,51331 Dec 247,136-6,8268,0741,67230 Sep 247,283-9,4427,6212,34730 Jun 247,662-6,7167,2162,55031 Mar 247,914-6,0797,1943,17931 Dec 239,761-5,5127,0763,08131 Dec 2238,08514,6028,7841,516質の高い収益: A225220は現在利益が出ていません。利益率の向上: A225220は現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A225220の過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: A225220の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: A225220は利益が出ていないため、過去 1 年間の収益成長をLife Sciences業界 ( -29.5% ) と比較することは困難です。株主資本利益率高いROE: A225220は現在利益が出ていないため、自己資本利益率 ( -18.55% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 10:49終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genolution Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.
お知らせ • Mar 17Genolution Inc., Annual General Meeting, Mar 27, 2026Genolution Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea
分析記事 • May 22Is Genolution (KOSDAQ:225220) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • Mar 08Genolution Inc., Annual General Meeting, Mar 28, 2025Genolution Inc., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea
New Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩44.5b market cap, or US$31.7m).
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩86.0b market cap, or US$64.6m).
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩73.9b market cap, or US$53.5m).
お知らせ • Jul 12Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Hana Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on January 9, 2024. As of July 9, 2023, the company had 656,993 treasury shares within scope available for dividend and no shares in treasury through other repurchase.
Valuation Update With 7 Day Price Move • May 16Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩4,785, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 35% over the past three years.
Upcoming Dividend • Dec 21Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.
お知らせ • Oct 06Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares.Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Shinyoung Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on April 5, 2023. As of October 5, 2022, the company had 516,512 treasury shares within scope available for dividend and no shares in treasury through other repurchase.
Upcoming Dividend • Sep 22Inaugural dividend of ₩200 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 31 October 2022. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩14,600, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 503% over the past three years.
Valuation Update With 7 Day Price Move • Nov 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩15,550, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 398% over the past three years.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses.
Valuation Update With 7 Day Price Move • Oct 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩13,400, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 285% over the past three years.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₩20,900, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 30x in the Life Sciences industry in South Korea. Total returns to shareholders of 415% over the past three years.
お知らせ • Jun 09Genolution Inc. announced that it has received KRW 5 billion in fundingOn June 8, 2021, Genolution Inc. closed the transaction.
お知らせ • Jun 05Genolution Inc. announced that it expects to receive KRW 5 billion in fundingGenolution Inc. (KOSDAQ:A225220) announced a private placement of non-guaranteed private convertible bonds for gross proceeds of KRW 5,000,000,000 on June 4, 2021. The transaction will involve participation from new investors including trustee funds 1, 2 managed by KB Securities Co., Ltd for KRW 1,000,000,000 and trustee fund 3 managed by NH Investment & Securities Co., Ltd for KRW 4,000,000,000. The bonds were issued at an interest rate of 1% and maturity rate of 1%.The bonds will be fully convertible into 315,417 common shares of the company at a fixed conversion price of KRW 15,852 per share between June 8, 2022 and May 8, 2026. The bonds will mature on June 08, 2026. The subscription date for the bonds is May 20, 2021 and payment date for the bonds is June 08, 2021. The transaction has been approved by the board of directors of the company.
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩17,850, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 72x in the Life Sciences industry in South Korea. Total returns to shareholders of 331% over the past three years.
分析記事 • Mar 17Could The Genolution Inc. (KOSDAQ:225220) Ownership Structure Tell Us Something Useful?If you want to know who really controls Genolution Inc. ( KOSDAQ:225220 ), then you'll have to look at the makeup of...
Is New 90 Day High Low • Mar 10New 90-day low: ₩24,550The company is down 10.0% from its price of ₩27,300 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 15% over the same period.
Is New 90 Day High Low • Jan 29New 90-day low: ₩24,800The company is down 36% from its price of ₩38,600 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period.
Is New 90 Day High Low • Nov 24New 90-day low: ₩25,800The company is down 26% from its price of ₩35,050 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Nov 03New 90-day high: ₩43,600The company is up 4.0% from its price of ₩41,750 on 05 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 4.0% over the same period.
お知らせ • Jul 18Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion.Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion. Security Name: Shares Security Type: Common Stock Securities Offered: 824,000 Price\Range: KRW 14000 Discount Per Security: KRW 840 Transaction Features: ESOP Related Offering